DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)

Information source: Translational Oncology Research International
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: Bevacizumab 7.5 and TAC (Drug); Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Drug); Bevacizumab 15 and TAC (Drug); Placebo 15 and TAC (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: Translational Oncology Research International

Official(s) and/or principal investigator(s):
Fairooz Kabbinavar, MD, Study Chair, Affiliation: Chief Medical Officer


The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.

Clinical Details

Official title: A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome:

•To evaluate the safety and toxicity of the TAC regimen with the addition of bevacizumab given as preoperative therapy to patients with Stage II or Stage III breast cancer

•To estimate change from baseline expression of HIF1α as a measure of tumor angiogenesis, after a single dose of bevacizumab as compared to placebo

Secondary outcome:

•To estimate the rate of CHF in patients receiving TAC with or without bevacizumab

•To estimate the rates of left ventricular ejection fraction (LVEF) changes as measured by either a decrease of > 15% from baseline, or > 10% to a value below the lower limit of normal (for the institution), in patients receiving TAC or TAC plus bevaciz

•To investigate the clinical efficacy of TAC and TAC plus bevacizumab by estimating the clinical objective response rate (CR + PR), pathologic complete response rate (pCR), and rate of breast-conserving surgery (BCS)

•To estimate the rate of post-surgical wound healing complications in patients who receive surgery after TAC or TAC plus bevacizumab

Detailed description: The study combines bevacizumab with a very efficacious combination chemotherapy regimen for the treatment of stage II or stage III primary breast cancer. Safety of the TAC-bevacizumab combination will be evaluated. In addition, the study design incorporates an initial cycle of bevacizumab or placebo alone. Assessing the isolated effects of bevacizumab in a setting where pre- and post-treatment tissue specimens can be obtained will provide essential information about the mechanisms by which VEGF inhibition affects tumor growth, and represents an ideal opportunity to evaluate the molecular effects of bevacizumab on breast tumor tissue.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- Histologically or cytologically proven adenocarcinoma of the breast

- Stage II (T > 3 cm) or Stage III disease (except inflammatory breast cancer),

according to the AJCC Staging Manual, 6th Edition, 2002

- HER2-negative disease (as defined by fluorescence in situ hybridization [FISH])

- ECOG performance status 0-1

- No prior chemotherapy, radiotherapy, or endocrine therapy for invasive or noninvasive

breast cancer

- Normal cardiac function (ejection fraction > lower limit of normal) as determined by

MUGA or echocardiogram

- Adequate organ function

Exclusion Criteria:

- Prior chemotherapy or radiotherapy for Stage II or Stage III breast cancer

- Inflammatory Breast Cancer, clinically defined as the presence of erythema or

induration involving one-third or more of the breast

- Prior treatment with an anti-angiogenic agent

- Prior ipsilateral radiation therapy for invasive or non-invasive breast cancer

- Bilateral invasive breast cancer

- Concurrent therapy with any other non-protocol anti-cancer therapy

- Current therapy with hormone replacement therapy, or any hormonal agent such as

raloxifene, tamoxifen, or other selective estrogen receptor modulators (agents must be stopped prior to randomization)

- Presence of neuropathy > grade 2 (NCI-CTC version 3. 0) at baseline

- Presence of any non-healing wound, bone fracture, or ulcer, or the presence of

clinically significant (> grade 2) peripheral vascular disease

- History of any other malignancy within the past 5 years, with the exception of

non-melanoma skin cancer or carcinoma-in-situ of the cervix

- Clinically significant cardiovascular disease (e. g., hypertension [BP > 150/100],

myocardial infarction or stroke within 6 months, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication

- Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal

condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning therapy

- Active, uncontrolled infection requiring parenteral antimicrobials

- The presence of any other medical or psychiatric disorder that, in the opinion of the

treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications

- Pregnancy or lactation

- A history of a severe hypersensitivity reaction to bevacizumab, or docetaxel or other

drugs formulated with polysorbate 80

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days

prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedure, fine needle aspiration, or core biopsy within 7 days prior to beginning therapy

- Urine protein: creatinine ratio of > 1. 0 at screening

Locations and Contacts

St. James's Hospital, Dublin 8, Ireland

St. Vincent's University Hospital, Dublin 4, Ireland

Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada

UCLA Medical Center, Los Angeles, California 90095, United States

Wilshire Oncology Medical Group, Inc., Pomona, California 91767, United States

Cancer Institute of Florida, P.A., Orlando, Florida 32804, United States

Northwest Georgia Oncology Centers, P.C., Marietta, Georgia 30060, United States

McGill University, Montreal, Quebec H2W 1S6, Canada

South Texas Oncology and Hematology, P.A., San Antonio, Texas 78207, United States

Additional Information

Starting date: April 2005
Last updated: February 16, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017